| 忻志鸣,叶根深,杨阳,等.辅助用药临床合理应用调查及管理对策[J].安徽医药,2017,21(8):1525-1528. |
| 辅助用药临床合理应用调查及管理对策 |
| Investigation on the clinical application of adjunct drugs and management strategies |
| 投稿时间：2016-08-22 |
| DOI： |
| 中文关键词: 辅助用药 管理 综合干预措施 |
| 英文关键词: Adjuvant drugs Management Comprehensive interventions |
| 基金项目: |
|
| 摘要点击次数: 2132 |
| 全文下载次数: 609 |
| 中文摘要: |
| 目的 促进辅助用药临床合理应用。方法 回顾性分析该院2013—2015年实施综合干预措施期间,辅助用药重点监测品种(KMAD)的品种类别、品种数及消耗金额等情况。结果 2013—2015年,KMAD的类别主要为活血化瘀及改善微循环类、神经营养类。各年度KMAD品种数构成比依次为5.19%、4.39%、3.88%；消耗金额构成比分别为46.36%、43.88%、41.49%,且差异有统计学意义(2013年与2014年相比,χ2=84 981.343,P＜0.001；2013年与2015年相比,χ2=30 2141.674,P＜0.001；2014年与2015年相比,χ2=76 754.880,P＜0.001)。结论 该院综合干预措施可促进辅助用药临床合理应用,取得成效。 |
| 英文摘要: |
| Objective To promote the clinical rational use of adjuvant drugs. Methods A retrospective analysis of the varieties numbers and consumption amount of key monitoring adjuvant drugs (KMAD) in our hospital during 2013—2015,when comprehensive interventions were implemented. Results From 2013 to 2015,drugs were mainly the blood circulation and microcirculation promoter,neurotrophic class.For each year,the varieties number ratios of KMAD were 5.19%,4.39% and 3.88%,respectively；the consumption amount ratios of KMAD were 46.36%,43.88% and 41.49%,respectively,and the difference was statistically significant (for 2013 vs 2014,χ2=84 981.343,P＜0.001；for 2013 vs 2015,χ2=302 141.674,P＜ 0.001；for 2014 vs 2015,χ2=76 754.880,P＜0.001). Conclusion Comprehensive interventions in our hospital can promote the clinical rational use of adjuvant drugs and achieved results. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
